Mingping Qian

Dr. Mingping Qian


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2022 in Frontiers in Chemistry
Verified
Journal Article
Open access
STShanshi Tong
Shanshi Tong
ZYZhilong Yu
Zhilong Yu
FYFang Yin
Fang Yin
QYQilin Yang
Qilin Yang
JCJuhang Chu
Juhang Chu
MQMingping Qian
Mingping Qian
Pancreatic cancer (PC) is one of the deadliest gastrointestinal malignancies. Advances in molecular biology and surgery have significantly improved survival rates for other tumors in recent decades, but clinical outcomes for PC remained relatively unchanged. Chemodynamic therapy (CDT) and Photothermal therapy (PTT) represent an efficient and relatively safe cancer treatment modality. Here, we synthesized Mn-doped Prussian blue nanoparticles (MnPB NPs) through a simple and mild method, which have a high loading capacity for drugs and excellent CDT/PTT effect. Cell line experiments in vitro and animal experiments in vivo proved the safety of MnPB NPs. We stimulated the PC cells with MnPB NPs and performed transwell migration assays. The migration of PC cells was reduced company with the decrease of two classical proteins: matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). Moreover, MnPB NPs induced ferroptosis, which mediated the MAPK pathway and achieved tumor elimination in nude mice. This effective and safe strategy controlled by irradiation represents a promising strategy for pancreatic cancer.

29 October 2023 in Clinics
Verified
Journal Article
Open access
JCJuhang Chu
Juhang Chu
LHLuyao Huang
Luyao Huang
YWYaru Wang
Yaru Wang
LFLin Fang
Lin Fang
MQMingping Qian
Mingping Qian
Objective: MicroRNAs play crucial roles in the pathogenesis of cancers. MiRNA-218-5p may act as either an onco-gene or a tumor suppressor, but its role in the pathogenesis of Breast Cancer (BC) remains unclear.Methods: Infiltrative breast ductal carcinoma as well as corresponding adjacent normal samples were collected from 30 patients. Mimics and inhibitors of miRNA-218-5p or corresponding negative controls were transfected into BC cells. miRNA-218-5p expression was detected by quantitative PCR. The effects of miRNA-218-5p on the malignant behaviors of BC were assessed. Dual-luciferase reporter assay was employed to evaluate the binding of miRNA-218-5p to LRIG1.Results: BC tissues showed higher miRNA-218-5p expression as compared to the adjacent normal tissues. Ectopic miRNA-218-5p expression accelerated the cell cycle, cell growth and migration of BC, while repressed cell apoptosis. Interestingly, ectopic miRNA-218-5p expression down-regulated LRIG1 expression, and miRNA-218-5p could bind to LRIG1. Also, our study indicated that miRNA-218-5p up-regulated ErbB2 and EGFR expression by targeting LRIG1, suggesting that the LRIG1-mediated signaling pathway contributed to the pro-tumor effects of miRNA-218-5p on BC.Conclusion: MiRNA-218-5p up-regulates ErbB2 and EGFR expression by suppressing LRIG1 expression, thus promoting the malignant behaviors of BC. miRNA-218-5p may exert a pro-tumor effect on BC and serve as a therapeutic target for BC treatment.

2 March 2021 in Research Square
Verified
Preprint
Open access
PDF file
MQMingping Qian
Mingping Qian
HXHui Xu
Hui Xu
HSHongming Song
Hongming Song
HXHao Xi
Hao Xi
LFLin Fang
Lin Fang
Background : MiR-218-5p is a small non-coding RNA acting as either oncogenes or tumor suppressor genes in human cancer. The expression levels of some miRNAs in human breast cancer plays a potential role in disease pathogenesis. Methods : Thirty pairs of invasive ductal carcinoma and adjacent specimens were included in the study. Breast tissues cell lines MCF-7 and MDA-MB-231 were identified as a breast cancer research cell line. MiR-218-5p mimics, miR-218-5p inhibitor, or negative controls were transfected. Specific antibodies were probed with LRIG1, ErbB2, and EGFR. Proliferation, migration, cell cycle and apoptosis, dual-luciferase reporter assay and immunohistochemistry were used to analyze miR-218-5p、LRIG1 and so on. Results : It was shown that miR-218-5p expression was higher in 30 breast cancer specimens than adjacent normal breast tissues. In human breast cancer cells MCF-7 and MDA-MB-231, restoring miR-218-5p promoted cell proliferation and migration and inhibited cell apoptosis and cell cycle arrest in the G1 stage. Luciferase assays indicated miR-218-5p could bind with its putative target site in the 3'-untranslated region (3'-UTR) of LRIG1. RT-qPCR, western blot, and immunocytochemistry analyses all indicated miR-218-5p overexpression results in LRIG1 downregulation at the mRNA and protein levels. ErbB2 and EGFR were found to be downstream effectors of miR-218-5p. Conclusion : MiR-218-5p promotes ErbB2 and EGFR expression by inhibiting LRIG1 in breast cancer cells, which suggests miR-218-5p and LRIG1 may act as an oncogene in breast cancer and it could be used as a therapeutic target for breast cancer treatments. Keywords: Breast cancer; miR-218-5p; LRIG1; Oncogene

22 April 2026 in Oncology Reviews
Verified
Journal Article
Open access
PDF file
ZWZi-Xin Wang
Zi-Xin Wang
JCJu-Hang Chu
Ju-Hang Chu
YWYa-Ru Wang
Ya-Ru Wang
LHLu-Yao Huang
Lu-Yao Huang
MQMingping Qian
Mingping Qian
Triple-negative breast cancer (TNBC), an aggressive subtype lacking estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, accounts for 10–20% of breast cancers and is characterized by high metastatic potential and poor survival outcomes. Despite advancements in chemotherapy, the 5-year survival rate for metastatic TNBC remains below 30%, underscoring the need for innovative therapeutic approaches. This review comprehensively examines recent breakthroughs in TNBC immunotherapy, focusing on immune checkpoint inhibitors (ICIs), combination strategies, and biomarker-driven therapy. Landmark trials such as KEYNOTE-355 and IMpassion130 have demonstrated that combining PD-1/PD-L1 inhibitors with chemotherapy improves survival in PD-L1-positive metastatic TNBC. Beyond monotherapy, combination therapies—including dual checkpoint inhibition, PARP inhibitors in BRCA-mutated tumors, and antibody-drug conjugates (ADCs) —show promise in overcoming resistance and enhancing antitumor immunity. Emerging targets further expand therapeutic possibilities, though their paradoxical roles as biomarkers and immunosuppressive mediators require precision-based approaches. Biomarkers like PD-L1, tumor-infiltrating lymphocytes (TILs), tumor mutational burden (TMB), and circulating tumor DNA (ctDNA) are critical for patient stratification and predicting immunotherapy response. Despite progress, challenges persist, including tumor heterogeneity, resistance mechanisms, and access to advanced therapies. Future directions emphasize next-generation ICIs, optimized combination regimens, and AI-driven biomarker integration to achieve durable, personalized treatments. This review underscores the potential of immunotherapy to redefine TNBC management while highlighting the imperative for continued innovation to address unmet clinical needs.

3 June 2025 in Clinics
Verified
Journal Article
Open access
JCJuhang Chu
Juhang Chu
LHLuyao Huang
Luyao Huang
YWYaru Wang
Yaru Wang
MQMingping Qian
Mingping Qian
To explore the relationship between PIK3CA mutations and clinicopathological features and prognosis in breast cancer patients. This retrospective cohort study included 283 patients with invasive breast cancer who underwent surgery from June 2017 to June 2022. PIK3CA exon 9 and 20 mutations were detected using PCR and sequencing. Patients were divided into recurrence (n = 47) and non-recurrence (n = 236) groups based on follow-up data to identify postoperative recurrence factors and build a prediction model. Kaplan-Meier analysis was used to evaluate recurrence rates. PIK3CA mutations were identified in 41% of patients, with exon 20 mutations being the most common (62.1%). Mutations correlated with tumor quadrant, histological subtype, clinical stage, perineural invasion, and high NLR (p < 0.05). Recurrence group patients showed higher BMI, multiple tumors, non-luminal types, advanced clinical stage, lymph node metastasis, and higher NLR (p < 0.05). Multivariate analysis identified high BMI, multiple tumors, lymph node metastasis, advanced clinical stage, and perineural invasion as independent recurrence risk factors (p < 0.05). Notably, no significant difference in disease-free survival was observed between PIK3CA mutant and wild-type patients (p > 0.05). PIK3CA mutations are associated with specific clinicopathological features but do not significantly impact prognosis in breast cancer patients.

17 November 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
LWLiwen Wei
Liwen Wei
DLDianjiang Li
Dianjiang Li
LHLongjun Hu
Longjun Hu
KWKuanlei Wang
Kuanlei Wang
QWQin Wang
Qin Wang
YZYouran Zhang
Youran Zhang
Objectives: To investigate how post-traumatic growth (PTG) and moral sensitivity influence service behaviour among healthcare workers (HCWs) in mainland China post-COVID-19, with a focus on the mediating role of moral sensitivity.Design: Cross- sectional survey design.Setting: This study was conducted in 27 provinces across mainland China, from 16 March to 2 April 2023.Participants: 1,193 HCWs, including 378 physicians and 815 nurses, were selected using convenience and snowball sampling methods.Methods: The survey included the Post-traumatic Growth Inventory-Chinese version (PTGI-C), the Moral Sensitivity Questionnaire-Revised Chinese Version (MSQ-R-CV) and a service behaviour scale. Structural equation modelling was employed to analyse the data, focusing on the associations between PTG, moral sensitivity, and service behaviours.Results: The study found significant associations between PTG and moral sensitivity (r=0.49, p<0.01), with both factors positively influencing HCWs’ service behaviours. Specifically, PTG had a direct effect on service behaviours (β=0.172, p<0.01) and an indirect effect through moral sensitivity (β=0.333, p<0.01), with moral sensitivity mediating 65.8% of PTG’s impact on service behaviours. The model explained 56.0% of the variance in service behaviours, indicating a substantial influence of these psychological factors on professional conduct.Conclusions: The findings highlight the significant role of PTG and moral sensitivity in shaping the service behaviours of HCWs in the aftermath of the COVID-19 pandemic. The study suggests that enhancing PTG and moral sensitivity through targeted interventions could improve HCWs’ service delivery and resilience, emphasising the importance of incorporating psychological and ethical training into healthcare practices to prepare for future public health crises.